Last edition
News about "Shanghai JMT-Bio Technology"
Four Drugs in Race for First Bispecific ADC Approval: GlobalData
With 21 global approvals, ADCs generated USD 13.6 billion in 2024. BsADCs represent further opportunities in this field, by leveraging bi-specific antibodies that simultaneously bind two distinct targets.
Shanghai JMT-Bio Technology | 02/09/2025 | By Dineshwori | 154
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members